Cancer Biomarkers Market

Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022

Report Code: MD 5627 Oct, 2019, by marketsandmarkets.com
Updated date -

[267 Pages Report] The global cancer biomarkers market is accounted for USD 10.31 billion in 2016 and is expected to grow at a CAGR of 12.2% to USD 20.48 billion by 2022 during the forecast period. Cancer biomarkers are substances or processes that are indicative of the presence of cancers in the human body. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. They can be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. They enhance cancer detection and facilitate high-speed noninvasive diagnosis using Genomics and proteomics.

Cancer Biomarkers Market - Attractive Opportunities in the Cancer Biomarkers Market

Pharmaceutical and biotech companies are increasingly focusing on the use of biomarkers in their drug discovery and development process and have formed strategic alliances for sharing technology for biomarker applications in large-stage clinical trials are fueling the growth of this market. The base year considered for the study is 2016, and the forecast has been provided for the period between 2017 and 2022.

Selected Market Dynamics in Cancer Biomarkers Market

Technological advancements

Over the last few years, fields, such as diagnostic imaging, immunoassays, omics technologies, and bioinformatics have witnessed significant technological advancements. Moreover, several companies operating in the diagnostic imaging market are focusing on developing technologically-advanced equipment that are more economical, provide better patient safety, and are easy to use.

Advancements in omics technologies enable faster acquisition of genomic, proteomic, and metabolomic data, and its integration with clinical trial data using advanced bioinformatics software. The omics revolution in the last decade has increased the applications of biomarkers in biomedical research. Also, developments in high-throughput genomic technologies are facilitating the identification and analysis of mutations and polymorphisms in key genes, thus expanding the spectrum of available genomic biomarkers. For instance, researchers at the Mayo Clinic have identified the role of mutations in the SPOP gene on the development of resistance to BET. With these advancements, the number of available genomic biomarkers for the detection of cancer is expected to increase.

Technical issues related to sample collection and storage

Many epidemiology studies use biomarkers to investigate different stages of diseases in humans. This requires careful handling and storage of precious biological samples for obtaining a large amount of information from limited samples and minimizing future research costs through the use of banked samples. Sample collection is thus one of the key issues for service providers, followed by the access to these samples. A stringent quality control of these samples is required and they need to be stored under the right conditions to avoid any loss. Also, different samples are required for risk detection, screening, diagnosis, and monitoring processes.

The validity of results from biomarkers studies using archived specimens depends on the integrity of specimens and the manner in which they are collected, processed, and stored. Apart from the maintenance of samples, specimen banks have to be structured so that all elements of patient rights, privacy, and confidentiality are addressed with an informed consent that is thorough and addresses the potential use of samples. Furthermore, detailed tracking, specimen storage, and retrieval software are required for proper sample handling and management. These issues are expected to hinder the growth of the overall cancer biomarkers market.

Cancer biomarkers Market : Objectives of the Study

  • To define, describe, and segment the global market by type, cancer type, profiling technology, application, and region
  • To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the global market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW)
  • To profile key players in the market and comprehensively analyze their market shares and core competencies2
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, and other developments in the cancer biomarkers market

Cancer biomarkers Market : Research Methodology

Top-down and bottom-up approaches were used to validate the size of the global Patient Lateral Transfer market and estimate the size of other dependent submarkets. Various secondary sources such as World Health Organization, World Bank, Centers for Disease Control and Prevention, National Institutes of Health, Canadian Institute of Health Information, National Cancer Institute, European Association for Cancer Research, Australian Cancer Research Foundation (ACRF), GLOBOCAN 2012, Cancer Journal for Clinicians, World Bank, U.S. Census Bureau, Canadian Institute of Health Information, databases, and annual reports of the companies have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of this market. The breakdown of profiles of primaries is shown in the figure below:

Genetic Biomarkers Market - Breakdown of Primary Interviews

To know about the assumptions considered for the study, download the pdf brochure

The market is dominated by established players such as Thermo Fisher Scientific, Roche Diagnostics, Agilent Technologies, Illumina, Abbott Laboratories, Qiagen N.V., Merck & Co., Becton Dickinson and Company, and Hologic.

Cancer biomarkers Market : Target Audience:

  • Manufacturing companies of diagnostics kits and imaging instrument providers
  • Biomarkers assay and reagent manufacturers, vendors, and distributors
  • Contract research organizations (CROs)
  • Companies offering platforms/technologies for cancer diagnosis
  • Market research and consulting firms
  • Venture capitalists and investors

Cancer biomarkers Market : Scope of the Report

  • The market study doesn’t cover the market size in terms of volume
  • Some companies in this market are privately owned and their revenues are not available in the public domain. Hence, revenue for those companies are not included in this report
  • Company developments not reported in the public domain are not included in this report

Particular

 

Historical Years

2015

Base Year

2016

Estimated Year

2017-e

Forecast Period

2017-e–2022-p

Revenue Currency

USD

Market Segmentation

This research report categorizes the cancer biomarker market on the basis of biomarker type, cancer type, profiling technology, application, and region.

Global Cancer Biomarker Market, By Type

  • Protein Biomarker
  • Genetic Biomarker
  • Other Cancer Biomarkers (cell, viral, and carbohydrate biomarkers)

Global Cancer Biomarker Market, By Cancer Type

  • Breast Cancer 
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Non-hodgkin’s lymphoma
  • Melanoma
  • Leukemia
  • Thyroid Cancer
  • Bladder Cancer
  • Kidney Cancer
  • Other Cancers (multiple myeloma, cervical, central nervous system cancer, gastric, liver, pancreatic, oral cavity and pharynx, stomach, and ovarian cancer

Global Cancer Biomarker Market, By Profiling Technology

  • Omics Technologies
  • Genomics
  • Proteomics
  • Other Omics Technology
  • Imaging Technologies
  • Ultrasound
  • CT
  • MRI
  • PET
  • Mammography
  • Immunoassays 
  • Cytogenetics
  • In Situ Hybridization
  • Other Cytogenetics
  • Bioinformatics

Global Cancer Biomarker Market, By Application

  • Diagnostics
  • Research
  • Prognostics
  • Risk Assessment
  • Other Applications (personalized medicine, surrogate endpoints, and therapeutics)

Global Cancer Biomarker market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (ROE)
  • Asia Pacific (APAC)
    • Japan
    • Rest of Asia Pacific (ROAPAC)
  • Rest of the World (ROW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Company Information, detailed analysis and profiling of additional market players (Up to 5)

The global cancer biomarker market is projected to reach USD 20.48 billion by 2022 from USD 11.53 billion in 2017, at a CAGR of 12.2% from 2017 to 2022.   

Major factors driving the growth of the market are rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies. However, the high cost of various cancer diagnostic tests, need for high capital investments, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection are restricting the growth of this market. In this report, the global cancer biomarker market is segmented on the basis of biomarker type, cancer type, profiling technology, application, and region.
    
Cancer biomarkers are substances or processes that are indicative of the presence of cancers in the human body. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. They can be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. They enhance cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics.

The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin’s lymphoma, kidney, and other cancers. In 2017, the breast cancer segment is expected to account for the largest share of the global market by cancer type. The largest share of this segment is mainly attributed to the high prevalence of breast cancer over the last few years, increased awareness about breast cancer diagnosis, and increasing research focus on breast cancer.

On the basis of biomarker type, the market segmented into protein biomarker, genetic biomarker, and other biomarkers. In 2017, the protein biomarkers segment is expected to account for the largest share of the global market. The large share of this segment is mainly attributed to the tremendous potential of protein biomarkers in cancer detection, diagnostics, prognostics, and clinical & therapeutic applications; and low cost of the protein biomarker tests as compared to genetic biomarker tests. The increasing focus of pharmaceutical companies towards the discovery of protein biomarkers is further expected to fuel the growth of this market during the forecast period.

On the basis of application, the market is classified into diagnostics, research and development, prognostics, risk assessment, and other applications. In 2017, the diagnostics segment is expected to account for largest share of the global cancer biomarkers market. The large share of this segment is mainly attributed to the rising incidences of cancer, increased awareness and acceptance of diagnostic tests, technological advancements, and the need for early-stage cancer diagnosis.

The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. While North America (comprising the U.S. and Canada) is expected to account for the largest share of the global cancer biomarker market in 2017. The Asia-Pacific cancer biomarker market, particularly in China, Japan, and India is expected to witness high growth in the forecast period. Factors such as rising incidence of cancer, increasing use of biomarker tests for diagnostic purposes, expansions of major pharmaceutical companies in emerging Asian economies, and government support to research institutes and universities are further drive the growth of this market in the APAC region.

Genetic Biomarkers Market, by Region, 2022, (USD billion)

Rising adoption of genomics technologies in drug discovery and clinical applications such as NGS and PCR are driving the growth of cancer biomarker market.

Next generation sequencing (NGS)

Sequencing is the process of determining the precise order of nucleotides in a DNA/RNA sample. The advent of rapid sequencing methods has greatly enhanced biological and medical research and the discovery of biomarkers. Next-generation Sequencing (NGS) is one of the most significant developments in genomics technologies with regards to cancer biomarker discovery, diagnostics, and prognostics. It has advanced the biomarker discovery process by accelerating the timeline of sequencing as R&D efforts are no longer bound to a single gene or small gene panels. Through massively parallel sequencing, this technology brings about faster identification of genetic diseases in specific populations or tissue types

Polymerase chain reaction (PCR)

Polymerase Chain Reaction (PCR) is a laboratory technique used to make multiple copies of a segment of DNA. It is very precise and can be used to amplify or copy a specific DNA target from a mixture of DNA molecules. It enables the detection of minimal residual disease and also detects cancer with genetic abnormalities. PCR can help define subgroups of patients that are suitable candidates for anti-cancer therapies. PCR-based diagnostic kits are used to detect several biomarkers such as B-Raf, Epidermal Growth Factor Receptor (EGFR), and Kristen Rat Sarcoma (KRAS), among others, to access specific mutations in clinical trial laboratories. They aid in selecting the right candidates in clinical trials for treatment with tailored drugs.

Critical questions the report answers:

  • Where will all these technologies take the industry in the mid to long term?
  • What are the segments which offers lucrative opportunity in cancer biomarker market?

Significant capital investments are required for the discovery, development, and validation of biomarkers. This is a major factor restraining the growth of the biomarkers market and other related markets such as diagnostics (in vitro diagnostics or companion diagnostics) and personalized medicine. The discovery of candidate biomarkers far outpaces the current ability to validate them. In addition, due to the high drug attrition in clinical trials (with almost 30% drugs failing in phase III), diagnostics manufacturers are facing significant financial challenges. To gain approval for an IVD from regulators, manufacturers need successful phase III clinical trials, which depend on well-validated biomarker tests. Huge investments are required to run clinical trials and address stringent regulatory requirements, which not only affects the ability of small companies to develop biomarkers but also severely affects innovation.

The cancer biomarkers market is dominated by established players such as Thermo Fisher Scientific, Roche Diagnostics, Agilent Technologies, Illumina, Abbott Laboratories, Qiagen N.V., Merck & Co., Becton Dickinson and Company, and Hologic.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 23)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Markets Covered
           1.2.2 Years Considered for the Study
    1.3 Currency
    1.4 Limitations
    1.5 Stakeholders

2 Research Methodology (Page No. - 26)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
           2.2.1 Secondary Sources
                    2.2.1.1 Key Industry Insights
    2.3 Assumptions for the Study

3 Executive Summary (Page No. - 34)

4 Premium Insights (Page No. - 38)
    4.1 Cancer Biomarkers: Market Snapshot
    4.2 APAC Cancer Biomarkers Market, By Profiling Technology and Application
    4.3 Cancer Biomarkers Market Share, By Cancer Type, 2017 vs 2022
    4.4 Cancer Biomarkers Market Share, By Biomarker Type, 2015 to 2022
    4.5 Cancer Biomarkers Market, By Region

5 Market Overview (Page No. - 42)
    5.1 Introduction
           5.1.1 Drivers
                    5.1.1.1 Technological Advancements
                    5.1.1.2 Rising Incidence of Cancer
                    5.1.1.3 Increasing Use of Cancer Biomarkers in Drug Discovery and Development
                    5.1.1.4 Increasing Research on Cancer Biomarkers
           5.1.2 Restraints
                    5.1.2.1 Unfavorable Regulatory and Reimbursement Scenario
                    5.1.2.2 High Amount of Capital Investments and Low Benefit-Cost Ratio
                    5.1.2.3 Technical Issues Related to Sample Collection and Storage
           5.1.3 Opportunities
                    5.1.3.1 Personalized Medicine
                    5.1.3.2 Companion Diagnostics
                    5.1.3.3 Emerging Economies
           5.1.4 Challenges
                    5.1.4.1 Proving Clinical Validity and Utility of Biomarker-Based Tests

6 Cancer Biomarkers Market, By Biomarker Type (Page No. - 48)
    6.1 Introduction
    6.2 Protein Biomarkers
    6.3 Genetic Biomarkers
           6.3.1 Lung Cancer
           6.3.2 Colorectal Cancer (CRC)
           6.3.3 Breast Cancer
           6.3.4 Prostate Cancer
           6.3.5 Leukemia
    6.4 Other Cancer Biomarkers

7 Cancer Biomarkers Market, By Cancer Type (Page No. - 62)
    7.1 Introduction
    7.2 Breast Cancer
    7.3 Lung Cancer
    7.4 CRC
    7.5 Prostate Cancer
    7.6 Non-Hodgkin’s Lymphoma (NHL)
    7.7 Melanoma
    7.8 Leukemia
    7.9 Thyroid Cancer
    7.10 Bladder Cancer
    7.11 Kidney Cancer
    7.12 Other Cancer Types

8 Cancer Biomarkers Market, By Profiling Technology (Page No. - 84)
    8.1 Introduction
           8.1.1 OMICS Technologies
           8.1.2 Proteomics
           8.1.3 Genomics
                    8.1.3.1 NGS
                    8.1.3.2 PCR
           8.1.4 Other OMICS Technologies
    8.2 Imaging Technologies
           8.2.1 Ultrasound
           8.2.2 CT
           8.2.3 MRI
           8.2.4 PET
           8.2.5 Mammography
    8.3 Immunoassays
    8.4 Cytogenetics
           8.4.1 ISH
           8.4.2 Other Cytogenetics-Based Tests
    8.5 Bioinformatics

9 Cancer Biomarkers Market, By Application (Page No. - 122)
    9.1 Introduction
    9.2 Diagnostics
    9.3 R&D
    9.4 Prognostics
    9.5 Risk Assessment
    9.6 Other Applications

10 Introduction (Page No. - 133)
     10.1 Introduction
     10.2 North America
             10.2.1 US
             10.2.2 Canada
     10.3 Europe
             10.3.1 Germany
             10.3.2 UK
             10.3.3 France
             10.3.4 Italy
             10.3.5 Spain
             10.3.6 RoE
     10.4 APAC
             10.4.1 Japan
             10.4.2 RoAPAC
     10.5 RoW
             10.5.1 Latin America
             10.5.2 Middle East & Africa

11 Cancer Biomarkers Market Share, By Cancer Type, 2017 vs 2022 (Page No. - 189)
     11.1 Market Ranking Analysis, 2016

12 Cancer Biomarkers Market, By Region (Page No. - 190)
     12.1 Thermo Fisher Scientific
             12.1.1 Overview
             12.1.2 Product and Services
             12.1.3 Financials
             12.1.4 Strategy & Development
             12.1.5 MnM View
     12.2 Bio-Rad Laboratories
             12.2.1 Overview
             12.2.2 Product and Services
             12.2.3 Financials
             12.2.4 Strategy & Development
             12.2.5 MnM View
     12.3 Roche Diagnostics
             12.3.1 Overview
             12.3.2 Product and Services
             12.3.3 Financials
             12.3.4 Strategy & Development
             12.3.5 MnM View
     12.4 Qiagen N.V.
             12.4.1 Overview
             12.4.2 Product and Services
             12.4.3 Financials
             12.4.4 Strategy & Development
             12.4.5 MnM View
     12.5 Illumina
             12.5.1 Overview
             12.5.2 Product and Services
             12.5.3 Financials
             12.5.4 Strategy & Development
     12.6 GE Healthcare
             12.6.1 Overview
             12.6.2 Product and Services
             12.6.3 Financials
             12.6.4 Strategy & Development
     12.7 Agilent Technologies
             12.7.1 Overview
             12.7.2 Product and Services
             12.7.3 Financials
             12.7.4 Strategy & Development
     12.8 Biomιrieux Sa
             12.8.1 Overview
             12.8.2 Product and Services
             12.8.3 Financials
             12.8.4 Strategy & Development
     12.9 Merck & Co.
             12.9.1 Overview
             12.9.2 Product and Services
             12.9.3 Financials
             12.9.4 Strategy & Development
     12.10 Abbott Laboratories
             12.10.1 Overview
             12.10.2 Product and Services
             12.10.3 Financials
             12.10.4 Strategy & Development
     12.11 Becton, Dickinson and Company
             12.11.1 Overview
             12.11.2 Product and Services
             12.11.3 Financials
             12.11.4 Strategy & Development
     12.12 Danaher Corporation
             12.12.1 Overview
             12.12.2 Product and Services
             12.12.3 Financials
             12.12.4 Strategy & Development
     12.13 Myriad Genetics
             12.13.1 Overview
             12.13.2 Product and Services
             12.13.3 Financials
             12.13.4 Strategy & Development
     12.14 Sysmex Corporation
             12.14.1 Overview
             12.14.2 Product and Services
             12.14.3 Financials
             12.14.4 Strategy & Development
     12.15 Hologic
             12.15.1 Overview
             12.15.2 Product and Services
             12.15.3 Financials
             12.15.4 Strategy & Development
     12.16 Quest Diagnostics
             12.16.1 Overview
             12.16.2 Product and Services
             12.16.3 Financials
             12.16.4 Strategy & Development

13 Competitive Landscape (Page No. - 239)
     13.1 Insights of Industry Experts
     13.2 Discussion Guide
     13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.4 Introducing RT: Real-Time Market Intelligence
     13.5 Available Customizations
     13.6 Related Reports
     13.7 Author Details

List of Tables (268 Tables)

Table 1 Cancer Biomarkers Market, By Biomarker Type, 2015–2022 (USD Million)
Table 2 Global Protein Cancer Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 3 North America: Protein Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 4 Europe: Protein Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 5 APAC: Protein Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 6 Global Genetic Cancer Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 7 North America: Genetic Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 8 Europe: Genetic Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 9 APAC: Genetic Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 10 Global Other Cancer Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 11 North America: Other Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 12 Europe: Other Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 13 APAC: Other Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 14 Global Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 15 Global Breast Cancer Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 16 North America: Breast Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 17 Europe: Breast Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 18 APAC: Breast Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 19 Global Lung Cancer Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 20 North America: Lung Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 21 Europe: Lung Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 22 APAC: Lung Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 23 Global CRC Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 24 North America: CRC Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 25 Europe: CRC Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 26 APAC: CRC Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 27 Global Prostate Cancer Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 28 North America: Prostate Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 29 Europe: Prostate Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 30 APAC: Prostate Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 31 Global NHL Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 32 North America: NHL Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 33 Europe: NHL Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 34 APAC: NHL Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 35 Global Melanoma Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 36 North America: Melanoma Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 37 Europe: Melanoma Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 38 APAC: Melanoma Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 39 Global Leukemia Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 40 North America: Leukemia Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 41 Europe: Leukemia Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 42 APAC: Leukemia Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 43 Global Thyroid Cancer Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 44 North America: Thyroid Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 45 Europe: Thyroid Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 46 APAC: Thyroid Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 47 Global Bladder Cancer Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 48 North America: Bladder Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 49 Europe: Bladder Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 50 APAC: Bladder Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 51 Global Kidney Cancer Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 52 North America: Kidney Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 53 Europe: Kidney Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 54 APAC: Kidney Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 55 Global Other Cancer Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 56 North America: Other Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 57 Europe: Other Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 58 APAC: Other Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 59 Global Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 60 Cancer Biomarkers Market for OMICS Technologies, By Type, 2015–2022 (USD Million)
Table 61 Cancer Biomarkers Market for OMICS Technologies, By Region, 2015–2022 (USD Million)
Table 62 North America: Cancer Biomarkers Market for OMICS Technologies, By Country, 2015–2022 (USD Million)
Table 63 Europe: Cancer Biomarkers Market for OMICS Technologies, By Country, 2015–2022 (USD Million)
Table 64 APAC: Cancer Biomarkers Market for OMICS Technologies, By Country, 2015–2022 (USD Million)
Table 65 Cancer Biomarkers Market for Proteomics, By Region, 2015–2022 (USD Million)
Table 66 North America: Cancer Biomarkers Market for Proteomics, By Country, 2015–2022 (USD Million)
Table 67 Europe: Cancer Biomarkers Market for Proteomics, By Country, 2015–2022 (USD Million)
Table 68 APAC: Cancer Biomarkers Market for Proteomics, By Country, 2015–2022 (USD Million)
Table 69 Cancer Biomarkers Market for Genomics, By Type, 2015–2022 (USD Million)
Table 70 Cancer Biomarkers Market for Genomics, By Region, 2015–2022 (USD Million)
Table 71 North America: Cancer Biomarkers Market for Genomics, By Country, 2015–2022 (USD Million)
Table 72 Europe: Cancer Biomarkers Market for Genomics, By Country, 2015–2022 (USD Million)
Table 73 APAC: Cancer Biomarkers Market for Genomics, By Country, 2015–2022 (USD Million)
Table 74 Cancer Biomarkers Market for NGS, By Region, 2015–2022 (USD Million)
Table 75 North America: Cancer Biomarkers Market for NGS, By Country, 2015–2022 (USD Million)
Table 76 Europe: Cancer Biomarkers Market for NGS, By Country, 2015–2022 (USD Million)
Table 77 APAC: Cancer Biomarkers Market for NGS, By Country, 2015–2022 (USD Million)
Table 78 Cancer Biomarkers Market for PCR, By Region, 2015–2022 (USD Million)
Table 79 North America: Cancer Biomarkers Market for PCR, By Country, 2015–2022 (USD Million)
Table 80 Europe: Cancer Biomarkers Market for PCR, By Country, 2015–2022 (USD Million)
Table 81 APAC: Cancer Biomarkers Market for PCR, By Country, 2015–2022 (USD Million)
Table 82 Cancer Biomarkers Market for Other OMICS Technologies, By Region, 2015–2022 (USD Million)
Table 83 North America: Cancer Biomarkers Market for Other OMICS Technologies, By Country, 2015–2022 (USD Million)
Table 84 Europe: Cancer Biomarkers Market for Other OMICS Technologies, By Country, 2015–2022 (USD Million)
Table 85 APAC: Cancer Biomarkers Market for Other OMICS Technologies, By Country, 2015–2022 (USD Million)
Table 86 Cancer Biomarkers Market for Imaging Technologies, By Type, 2015–2022 (USD Million)
Table 87 Cancer Biomarkers Market for Imaging Technologies, By Region, 2015–2022 (USD Million)
Table 88 North America: Cancer Biomarkers Market for Imaging Technologies, By Country, 2015–2022 (USD Million)
Table 89 Europe: Cancer Biomarkers Market for Imaging Technologies, By Country, 2015–2022 (USD Million)
Table 90 APAC: Cancer Biomarkers Market for Imaging Technologies, By Country, 2015–2022 (USD Million)
Table 91 Cancer Biomarkers Market for Ultrasound, By Region, 2015–2022 (USD Million)
Table 92 North America: Cancer Biomarkers Market for Ultrasound, By Country, 2015–2022 (USD Million)
Table 93 Europe: Cancer Biomarkers Market for Ultrasound, By Country, 2015–2022 (USD Million)
Table 94 APAC: Cancer Biomarkers Market for Ultrasound, By Country, 2015–2022 (USD Million)
Table 95 Cancer Biomarkers Market for CT, By Region, 2015–2022 (USD Million)
Table 96 North America: Cancer Biomarkers Market for CT, By Country, 2015–2022 (USD Million)
Table 97 Europe: Cancer Biomarkers Market for CT, By Country, 2015–2022 (USD Million) 104
Table 98 APAC: Cancer Biomarkers Market for CT, By Country, 2015–2022 (USD Million) 105
Table 99 Cancer Biomarkers Market for MRI, By Region, 2015–2022 (USD Million) 106
Table 100 North America: Cancer Biomarkers Market for MRI, By Country, 2015–2022 (USD Million) 106
Table 101 Europe: Cancer Biomarkers Market for MRI, By Country, 2015–2022 (USD Million) 106
Table 102 APAC: Cancer Biomarkers Market for MRI, By Country, 2015–2022 (USD Million) 107
Table 103 Cancer Biomarkers Market for Pet, By Region, 2015–2022 (USD Million) 107
Table 104 North America: Cancer Biomarkers Market for Pet, By Country, 2015–2022 (USD Million)
Table 105 Europe: Cancer Biomarkers Market for Pet, By Country, 2015–2022 (USD Million)
Table 106 APAC: Cancer Biomarkers Market for Pet, By Country, 2015–2022 (USD Million)
Table 107 Cancer Biomarkers Market for Mammography, By Region, 2015–2022 (USD Million)
Table 108 North America: Cancer Biomarkers Market for Mammography, By Country, 2015–2022 (USD Million)
Table 109 Europe: Cancer Biomarkers Market for Mammography, By Country, 2015–2022 (USD Million)
Table 110 APAC: Cancer Biomarkers Market for Mammography, By Country, 2015–2022 (USD Million)
Table 111 Cancer Biomarkers Market for Immunoassays, By Region, 2015–2022 (USD Million)
Table 112 North America: Cancer Biomarkers Market for Immunoassays, By Country, 2015–2022 (USD Million)
Table 113 Europe: Cancer Biomarkers Market for Immunoassays, By Country, 2015–2022 (USD Million)
Table 114 APAC: Cancer Biomarkers Market for Immunoassays, By Country, 2015–2022 (USD Million)
Table 115 Cancer Biomarkers Market for Cytogenetics, By Region, 2015–2022 (USD Million)
Table 116 North America: Cancer Biomarkers Market for Cytogenetics, By Country, 2015–2022 (USD Million)
Table 117 Europe: Cancer Biomarkers Market for Cytogenetics, By Country, 2015–2022 (USD Million)
Table 118 APAC: Cancer Biomarkers Market for Cytogenetics, By Country, 2015–2022 (USD Million)
Table 119 Cancer Biomarkers Market for ISH, By Region, 2015–2022 (USD Million)
Table 120 North America: Cancer Biomarkers Market for ISH, By Country, 2015–2022 (USD Million)
Table 121 Europe: Cancer Biomarkers Market for ISH, By Country, 2015–2022 (USD Million)
Table 122 APAC: Cancer Biomarkers Market for ISH, By Country, 2015–2022 (USD Million)
Table 123 Cancer Biomarkers Market for Other Cytogenetics-Based Tests, By Region, 2015–2022 (USD Million)
Table 124 North America: Cancer Biomarkers Market for Other Cytogenetics-Based Tests, By Country, 2015–2022 (USD Million)
Table 125 Europe: Cancer Biomarkers Market for Other Cytogenetics-Based Tests, By Country, 2015–2022 (USD Million)
Table 126 APAC: Cancer Biomarkers Market for Other Cytogenetics-Based Tests, By Country, 2015–2022 (USD Million)
Table 127 Global Cancer Biomarkers Market for Bioinformatics, By Region, 2015–2022 (USD Million)
Table 128 North America: Cancer Biomarkers Market for Bioinformatics, By Country, 2015–2022 (USD Million)
Table 129 Europe: Cancer Biomarkers Market for Bioinformatics, By Country, 2015–2022 (USD Million)
Table 130 APAC: Cancer Biomarkers Market for Bioinformatics, By Country, 2015–2022 (USD Million)
Table 131 Global Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 132 Global Cancer Biomarkers Market for Diagnostics, By Region, 2015–2022 (USD Million)
Table 133 North America: Cancer Biomarkers Market for Diagnostics, By Country, 2015–2022 (USD Million)
Table 134 Europe: Cancer Biomarkers Market for Diagnostics, By Country, 2015–2022 (USD Million)
Table 135 APAC: Cancer Biomarkers Market for Diagnostics, By Country, 2015–2022 (USD Million)
Table 136 Global Cancer Biomarkers Market for R&D, By Region, 2015–2022 (USD Million)
Table 137 North America: Cancer Biomarkers Market for R&D, By Country, 2015–2022 (USD Million)
Table 138 Europe: Cancer Biomarkers Market for R&D, By Country, 2015–2022 (USD Million)
Table 139 APAC: Cancer Biomarkers Market for R&D, By Country, 2015–2022 (USD Million)
Table 140 Global Cancer Biomarkers Market for Prognostics, By Region, 2015–2022 (USD Million)
Table 141 North America: Cancer Biomarkers Market for Prognostics, By Country, 2015–2022 (USD Million)
Table 142 Europe: Cancer Biomarkers Market for Prognostics, By Country, 2015–2022 (USD Million)
Table 143 APAC: Cancer Biomarkers Market for Prognostics, By Country, 2015–2022 (USD Million)
Table 144 Global Cancer Biomarkers Market for Risk Assessment, By Region, 2015–2022 (USD Million)
Table 145 North America: Cancer Biomarkers Market for Risk Assessment, By Country, 2015–2022 (USD Million)
Table 146 Europe: Cancer Biomarkers Market for Risk Assessment, By Country, 2015–2022 (USD Million)
Table 147 APAC: Cancer Biomarkers Market for Risk Assessment, By Country, 2015–2022 (USD Million)
Table 148 Global Cancer Biomarkers Market for Other Applications, By Region, 2015–2022 (USD Million)
Table 149 North America: Cancer Biomarkers Market for Other Applications, By Country, 2015–2022 (USD Million)
Table 150 Europe: Cancer Biomarkers Market for Other Applications, By Country, 2015–2022 (USD Million)
Table 151 APAC: Cancer Biomarkers Market for Other Applications, By Country, 2015–2022 (USD Million)
Table 152 Global Cancer Biomarkers Market, By Region, 2015–2022 (USD Million)
Table 153 North America: Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 154 North America: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 155 North America: Cancer Biomarkers Market, By Biomarker Type, 2015–2022 (USD Million)
Table 156 North America: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 157 North America: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 158 North America: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 159 North America: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 160 North America: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 161 North America: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 162 US: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 163 US: Cancer Biomarkers Market, By Biomarker Type, 2015–2022 (USD Million)
Table 164 US: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 165 US: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 166 US: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 167 US: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 168 US: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 169 US: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 170 Canada: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 171 Canada: Cancer Biomarkers Market, By Biomarker Type, 2015–2022 (USD Million)
Table 172 Canada: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 173 Canada: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 174 Canada: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 175 Canada: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 176 Canada: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 177 Canada: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 178 Europe: Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 179 Europe: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 180 Europe: Cancer Biomarkers Market, By Biomarker Type, 2015–2022 (USD Million)
Table 181 Europe: Cancer Biomarkers Market, By Profiling Technology,2015–2022 (USD Million)
Table 182 Europe: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 183 Europe: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 184 Europe: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 185 Europe: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 186 Europe: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 187 Germany: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 188 Germany: Cancer Biomarkers Market, By Biomarker Type, 2015–2022 (USD Million)
Table 189 Germany: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 190 Germany: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 191 Germany: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 192 Germany: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 193 Germany: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 194 Germany: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 195 UK: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 196 UK: Cancer Biomarkers Market, By Biomarker Type, 2015–2022 (USD Million)
Table 197 UK: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 198 UK: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 199 UK: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 200 UK: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 201 UK: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 202 UK: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 203 France: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 204 France: Cancer Biomarkers Market, By Biomarker Type, 2015–2022 (USD Million)
Table 205 France: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 206 France: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 207 France: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 208 France: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 209 France: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 210 France: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 211 Italy: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 212 Italy: Cancer Biomarkers Market, By Biomarker Type, 2015–2022 (USD Million)
Table 213 Italy: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 214 Italy: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 215 Italy: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 216 Italy: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 217 Italy: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 218 Italy: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 219 Spain: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 220 Spain: Cancer Biomarkers Market, By Biomarker Type, 2015–2022 (USD Million)
Table 221 Spain: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 222 Spain: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 223 Spain: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 224 Spain: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 225 Spain: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 226 Spain: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 227 RoE: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 228 RoE: Cancer Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 229 RoE: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 230 RoE: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 231 RoE: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 232 RoE: Imaging Technologies Market, 2015–2022 (USD Million)
Table 233 RoE: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 234 RoE: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 235 APAC: Cancer Biomarkers Market, By Country, 2015–2022 (USD Million)
Table 236 APAC: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 237 APAC: Cancer Biomarkers Market, By Biomarker Type, 2015–2022 (USD Million)
Table 238 APAC: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 239 APAC: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 240 APAC: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 241 APAC: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 242 APAC: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 243 APAC: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 244 Japan: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 245 Japan: Cancer Biomarkers Market, By Type, 2015–2022 (USD Million)
Table 246 Japan: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 247 Japan: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 248 Japan: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 249 Japan: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 250 Japan: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 251 Japan: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 252 RoAPAC: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 253 RoAPAC: Cancer Biomarkers Market, By Biomarker Type, 2015–2020 (USD Million)
Table 254 RoAPAC: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 255 RoAPAC: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 256 RoAPAC: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 257 RoAPAC: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 258 RoAPAC: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 259 RoAPAC: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 260 RoW: Cancer Biomarkers Market, By Cancer Type, 2015–2022 (USD Million)
Table 261 RoW: Cancer Biomarkers Market, By Biomarker Type, 2015–2022 (USD Million)
Table 262 RoW: Cancer Biomarkers Market, By Profiling Technology, 2015–2022 (USD Million)
Table 263 RoW: OMICS Technologies Market, By Type, 2015–2022 (USD Million)
Table 264 RoW: Genomics Technologies Market, By Type, 2015–2022 (USD Million)
Table 265 RoW: Imaging Technologies Market, By Type, 2015–2022 (USD Million)
Table 266 RoW: Cytogenetics Market, By Type, 2015–2022 (USD Million)
Table 267 RoW: Cancer Biomarkers Market, By Application, 2015–2022 (USD Million)
Table 268 Rank of Companies in the Global Cancer Biomarkers Market, 2016

 
List of Figures (37 Figures)

 
Figure 1 Research Design
Figure 2 Bottom-Up Approach
Figure 3 Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation
Figure 6 Cancer Biomarkers Market, By Cancer Type, 2017 vs 2022 (USD Million)
Figure 7 Cancer Biomarkers Market, By Biomarker Type, 2017 vs 2022 (USD Million)
Figure 8 Cancer Biomarkers Market, By Application, 2017 vs 2022 (USD Million)
Figure 9 Cancer Biomarkers Market, By Profiling Technology, 2017 vs 2022 (USD Million)
Figure 10 Geographical Snapshot of the Cancer Biomarkers Market
Figure 11 Technological Advancements A Major Driver for Cancer Biomarkers Market in 2017
Figure 12 Cancer Biomarkers Market: Drivers, Restraints, Opportunities, and Challenges
Figure 13 Genetic Biomarkers to Register Highest CAGR, 2017-2022 (USD Million)
Figure 14 Mutation Rate of Cell Surface Receptor Biomarkers in Breast Tumor
Figure 15 Global Cancer Biomarkers Market, By Cancer Type, 2017-2022 (USD Million)
Figure 16 OMICS Technologies Segment to Lead Global Cancer Biomarkers Market, 2017-2022 (USD Million)
Figure 17 Diagnostics Application Segment to Lead Cancer Biomarkers Market, 2017-2022 (USD Million)
Figure 18 Cancer Biomarkers Market: Geographic Snapshot (2017–2022)
Figure 19 North America Market Snapshot
Figure 20 Europe Market Snapshot
Figure 21 APAC Market Snapshot
Figure 22 Thermo Fisher Scientific: Company Snapshot (2016)
Figure 23 Bio-Rad Laboratories: Company Snapshot (2016)
Figure 24 Roche Diagnostics: Company Snapshot (2016)
Figure 25 Qiagen N.V.: Company Snapshot (2016)
Figure 26 Illumina: Company Snapshot (2016)
Figure 27 GE Healthcare: Company Snapshot (2016)
Figure 28 Agilent Technologies: Company Snapshot (2016)
Figure 29 Biomιrieux SA: Company Snapshot (2016)
Figure 30 Merck & Co.Inc.: Company Snapshot (2016)
Figure 31 Abbott Laboratories: Company Snapshot (2016)
Figure 32 Becton, Dickinson and Company: Company Snapshot (2016)
Figure 33 Danaher Corporation: Company Snapshot (2016)
Figure 34 Myriad Genetics Inc.: Company Snapshot (2016)
Figure 35 Sysmex Corporation: Company Snapshot (2016)
Figure 36 Hologic: Company Snapshot (2016)
Figure 37 Quest Diagnostics: Company Snapshot (2016)


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
MD 5627
Published ON
Oct, 2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cancer Biomarkers Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

...

Digital Virtual Assistant - MarketsandMarkets

Home